PET/CT in Hodgkin Lymphoma: An Update

Area of Science:

• Nuclear Medicine
• Oncology
• Radiology

Background:

• 18F-FDG-PET/CT is integral to Hodgkin's lymphoma (HL) management.
• It's used for staging and end-of-treatment response assessment.
• Interim PET/CT guides early treatment adaptation based on response.

Purpose of the Study:

• To review current PET/CT applications in HL.
• To discuss strengths, limitations, and emerging quantitative metrics.
• To explore PET/CT's role in immunotherapy response assessment.

Main Methods:

• Review of current literature and clinical practice guidelines.
• Discussion of quantitative PET metrics (SUV, MTV, TLG).
• Analysis of PET/CT's utility in staging, interim assessment, and treatment response.

Main Results:

• PET/CT is standard for staging and response assessment in HL.
• Interim PET/CT enables risk-adapted therapy.
• Quantitative metrics show promise for improved prediction but face challenges in standardization and positive predictive value.

Conclusions:

• PET/CT is essential for HL management, offering prognostic and therapeutic guidance.
• Quantitative PET metrics are evolving for precision medicine applications.
• Further research is needed to overcome limitations and optimize PET/CT utilization in HL.